Provider: S&P Capital IQ Quantitative Report
Provider: Laidlaw & Company
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Isis Pharmaceuticals Inc Publishes Data Demonstrating Antisense Targeting Of ApoC-III Significantly Reduces ApoC-III And Triglycerides
Isis Pharmaceuticals Inc announced publication of new data in journal Circulation Research [doi:10.1161/CIRCRESAHA.111.300367] demonstrating that antisense targeting of apolipoprotein C-III (apoC-III) resulted in reductions in apoC-III and triglycerides, each an independent risk factor for cardiovascular disease. Hypertriglyceridemia is a serious medical condition associated with premature coronary artery disease and an increased risk for pancreatitis. Isis is developing antisense apoC-III inhibitor, ISIS-APOCIIIRx, for the treatment of patients with severe hypertriglyceridemia and plans to report top-line data in the middle of this year. Treatment with an antisense compound targeting apoC-III produced a variety of potential cardio-protective effects including dose-dependent reductions of apoC-III and triglycerides in all models and species, including man. In addition, treatment with an antisense compound targeting apoC-III resulted in enhanced triglyceride clearance from blood following a high-fat meal, reduction of VLDL particles and a slight increase in HDL-C levels. In all models and in the Phase 1 study, antisense inhibition of apoC-III was well tolerated. These data were consistent across multiple preclinical models and species and in a Phase 1 study in healthy volunteers demonstrating that Isis' antisense technology was able to produce predictable and consistent responses among different animal models that translate into corresponding activity in man.
Latest Developments for Isis Pharmaceuticals Inc
- ISIS Pharmaceuticals reports positive phase 1 data demonstrating ISIS-PKK Rx produces reductions in Prekallikrein Levels
- Isis Pharmaceuticals Inc improves FY 2014 net operating loss outlook
- Isis Pharmaceuticals Inc reports positive phase 2 data for ISIS-FXI Rx
- Isis Pharmaceuticals Inc raises FY 2014 EBIT guidance
Latest Key Developments in Biotechnology
- Share this
- Digg this